emtricitabinetenofovir sold brand name truvada among others fixeddose combination antiretroviral medication used treat prevent contains antiretroviral medications emtricitabine tenofovir treatment must used combination antiretroviral prevention exposure high risk recommended along safer sex cure emtricitabinetenofovir taken common side effects include headache tiredness trouble sleeping abdominal pain weight loss serious side effects may include high blood lactate levels enlargement use medication pregnancy appear harm fetus well emtricitabinetenofovir approved medical use united states world health organizations list essential united states emtricitabinetenofovir patent gilead available generic commonly prescribed medication united states million emtricitabinetenofovir used treat prevent us national institutes health nih recommends antiretroviral therapy art people centers disease control prevention cdc recommends use emtricitabinetenofovir preexposure prophylaxis prep uninfected negative individuals may risk cochrane systematic review found relative risk reduction contracting hiv tenofovir alone tenofoviremtricitabine jama systematic review found similar relative risk reduction average greater reduction greater approved prep hiv infection united states cdc recommends prep considered following highrisk consideration utilizing emtricitabinetenofovir reduction strategy involves discussion health professional help patient navigate benefits risks patients advised discuss history bone issues kidney issues hepatitis b infection health care effectiveness prep prevention infection reliant individuals ability take medication emtricitabinetenofovir also used hiv postexposure prophylaxis people start taking emtricitabinetenofovir see hiv reduction benefit hours starting medicine must taken thirty days highrisk sexual event ensure hiv transmission levels optimally truvada prep used individuals positive emtricitabinetenofovir approved united states part antiretroviral combination therapy treatment combination therapy suggested one options adults received prior treatment hiv emtricitabine tenofovir indicated treatment hepatitis b added benefit target hiv emtricitabinetenofovir may also considered antiviral resistant hepatitis b united states recommend pregnant hivinfected women start antiretroviral therapy art early pregnancy possible reduce risk transmission art generally increase risk birth defects exception dolutegravir recommended first trimester pregnancy due potential risk neural tube emtricitabinetenofovir secreted breast developed countries hivinfected mothers generally recommended breastfeed due slight risk mothertochildren hiv developing countries avoiding breastfeeding may option world health organization recommends triple drug regimen tenofovir efavirenz either lamivudine emtricitabinetenofovir generally well tolerated side effects fat redistribution accumulation lipodystrophy observed people receiving antiretroviral therapy including fat reductions face limbs buttocks increases visceral fat abdomen accumulations upper used preexposure prophylaxis prep effect may weight changes however linked drugs adverse reactions include dabigatran etexilate lamivudine vincristine dabigatran etexilate used pglycoprotein inducers require monitoring decreased levels effects dabigatran lamivudine may increase adverse toxic effect emtricitabine vincristine used inducers decrease serum concentration patent drug combination owned gilead sciences regions european patent expired july gilead sciences wished patent extended however four rival accord healthcare lupin sought overturned courts britain high court england wales invalidated gileads however company appealed uk referred case european court justice refused extend irish court rejected injunction request prevent launch generic emtricitabinetenofovir prior resolution despite expiration gilead sciences patent still widespread challenges availability uptake generic prep throughout europe gilead sciences challenged validity patents granted united states using drug combination hiv prep postexposure prophylaxis united states healthcare plans required cover prep without copay cost sharing due united states preventive services task force recommendation gave prep grade rating affordable care act recommendation requires nongrandfathered private health plans cover prep without cost united kingdom prep widely available risk groups following department health social cares decision make available across england wales scotland northern ireland made available httpsenwikipediaorgwikiemtricitabinetenofovir